-
1
-
-
0141725532
-
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
-
Atalay G, Cardoso F, Awada A, Piccart MJ (2003) Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 14: 1346-1363
-
(2003)
Ann Oncol
, vol.14
, pp. 1346-1363
-
-
Atalay, G.1
Cardoso, F.2
Awada, A.3
Piccart, M.J.4
-
3
-
-
0032127350
-
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
-
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831
-
(1998)
Cancer Res
, vol.58
, pp. 2825-2831
-
-
Baselga, J.1
Norton, L.2
Albanell, J.3
Kim, Y.M.4
Mendelsohn, J.5
-
4
-
-
0033373265
-
The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependentcellular cytotoxicity and complement-dependent cytotoxicity in vitro
-
Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL (1999) The Ch14.18-GM-CSF fusion protein is effective at mediating antibody- dependentcellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 5: 4259-4263
-
(1999)
Clin Cancer Res
, vol.5
, pp. 4259-4263
-
-
Batova, A.1
Kamps, A.2
Gillies, S.D.3
Reisfeld, R.A.4
Yu, A.L.5
-
5
-
-
0031880576
-
A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression
-
Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, Windsor K, Gore I, Cantrell J, Thompson KA, Taylor WR, Barnes HM, Schiff SA, Shields JA, Cambareri RJ, Butler TP, Meister RJ, Feigert JM, Norgard MJ, Moraes MA, Helvie WW, Patton GA, Mundy LJ, Henry D, Mason B, Staddon A, Ford P, Katcher D, Houck W, Major WB, Gemma NW, Kay G, Priest E, Sowroy P, Bank B, Leibach S, Reisel H, Grad G, Warren RD, Ueno WM, Smith LF, Dobrzynski RF, Sheridan MJ (1998) A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 16: 366-373
-
(1998)
Cancer Invest
, vol.16
, pp. 366-373
-
-
Beveridge, R.A.1
Miller, J.A.2
Kales, A.N.3
Binder, R.A.4
Robert, N.J.5
Harvey, J.H.6
Windsor, K.7
Gore, I.8
Cantrell, J.9
Thompson, K.A.10
Taylor, W.R.11
Barnes, H.M.12
Schiff, S.A.13
Shields, J.A.14
Cambareri, R.J.15
Butler, T.P.16
Meister, R.J.17
Feigert, J.M.18
Norgard, M.J.19
Moraes, M.A.20
Helvie, W.W.21
Patton, G.A.22
Mundy, L.J.23
Henry, D.24
Mason, B.25
Staddon, A.26
Ford, P.27
Katcher, D.28
Houck, W.29
Major, W.B.30
Gemma, N.W.31
Kay, G.32
Priest, E.33
Sowroy, P.34
Bank, B.35
Leibach, S.36
Reisel, H.37
Grad, G.38
Warren, R.D.39
Ueno, W.M.40
Smith, L.F.41
Dobrzynski, R.F.42
Sheridan, M.J.43
more..
-
6
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
-
(1999)
J Clin Oncol
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
7
-
-
0347302952
-
Cytokines in cancer pathogenesis and cancer therapy
-
Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 11-22
-
-
Dranoff, G.1
-
8
-
-
0023943270
-
Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
-
Drebin JA, Link VC, Greene MI (1988) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387-394
-
(1988)
Oncogene
, vol.2
, pp. 387-394
-
-
Drebin, J.A.1
Link, V.C.2
Greene, M.I.3
-
9
-
-
0025060402
-
The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells
-
Erbe DV, Collins J, Shen L, Graxiano RF, Fanger MW (1990) The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells. Mol Immunol 27: 57-67
-
(1990)
Mol Immunol
, vol.27
, pp. 57-67
-
-
Erbe, D.V.1
Collins, J.2
Shen, L.3
Graxiano, R.F.4
Fanger, M.W.5
-
10
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808
-
(2002)
J Clin Oncol
, vol.20
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
Guerra, L.T.4
Murray, J.L.5
Pusztai, L.6
Cristofanilli, M.7
Arun, B.8
Esmaeli, B.9
Fritsche, H.A.10
Sneige, N.11
Smith, T.L.12
Hortobagyi, G.N.13
-
11
-
-
0021720154
-
Purified human granulocyte-macrophage colony stimulating factor: Direct action on neutrophils
-
Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Hewick RM, Wong GG, Golde DW (1984) Purified human granulocyte-macrophage colony stimulating factor: direct action on neutrophils. Science 226: 1339-1342
-
(1984)
Science
, vol.226
, pp. 1339-1342
-
-
Gasson, J.C.1
Weisbart, R.H.2
Kaufman, S.E.3
Clark, S.C.4
Hewick, R.M.5
Wong, G.G.6
Golde, D.W.7
-
12
-
-
0022478367
-
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
-
Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon PJ (1986) Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506-508
-
(1986)
Science
, vol.232
, pp. 506-508
-
-
Grabstein, K.H.1
Urdal, D.L.2
Tushinski, R.J.3
Mochizuki, D.Y.4
Price, V.L.5
Cantrell, M.A.6
Gillis, S.7
Conlon, P.J.8
-
13
-
-
10344242915
-
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer
-
Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS (1996) Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 14: 2976-2983
-
(1996)
J Clin Oncol
, vol.14
, pp. 2976-2983
-
-
Jones, S.E.1
Schottstaedt, M.W.2
Duncan, L.A.3
Kirby, R.L.4
Good, R.H.5
Mennel, R.G.6
George, T.K.7
Snyder, D.A.8
Watkins, D.L.9
Denham, C.A.10
Hoyes, F.A.11
Rubin, A.S.12
-
14
-
-
0036888489
-
Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen
-
Kim KM, Shin EY, Moon JH, Heo TH, Lee JY, Chung Y, Lee YJ, Cho HM, Shin SU, Kang CY (2002) Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int J Cancer 102: 428-434
-
(2002)
Int J Cancer
, vol.102
, pp. 428-434
-
-
Kim, K.M.1
Shin, E.Y.2
Moon, J.H.3
Heo, T.H.4
Lee, J.Y.5
Chung, Y.6
Lee, Y.J.7
Cho, H.M.8
Shin, S.U.9
Kang, C.Y.10
-
15
-
-
23444446779
-
Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma
-
Kurbacher CM, Kurbacher JA, Cramer EM, Rhiem K, Mallman PK, Reichelt R, Reinhold U, Stier U, Cree IA (2005) Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology 19(4 suppl 2): 23-26
-
(2005)
Oncology
, vol.19
, Issue.4 SUPPL. 2
, pp. 23-26
-
-
Kurbacher, C.M.1
Kurbacher, J.A.2
Cramer, E.M.3
Rhiem, K.4
Mallman, P.K.5
Reichelt, R.6
Reinhold, U.7
Stier, U.8
Cree, I.A.9
-
16
-
-
0024358410
-
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
-
Kushner BH, Cheung NK (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73: 1936-1941
-
(1989)
Blood
, vol.73
, pp. 1936-1941
-
-
Kushner, B.H.1
Cheung, N.K.2
-
18
-
-
0025903770
-
Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity
-
Liesveld JL, Frediani D, Winslow JM, Duerst RE, Abboud CN (1991) Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J Cell Biochem 45: 381-390
-
(1991)
J Cell Biochem
, vol.45
, pp. 381-390
-
-
Liesveld, J.L.1
Frediani, D.2
Winslow, J.M.3
Duerst, R.E.4
Abboud, C.N.5
-
19
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
Mascarenhas, D.4
Pollak, M.5
-
20
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
Chan, S.7
Grimes, D.8
Antón, A.9
Lluch, A.10
Kennedy, J.11
O'Byrne, K.12
Conte, P.13
Green, M.14
Ward, C.15
Mayne, K.16
Extra, J.M.17
-
21
-
-
0026341175
-
Therapy of colorectal carcinoma with monoclonal antibodies (Mab17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)
-
Mellstedt H, Frödin JE, Ragnhammar P, Masucci G, Ljungberg A, Hjelm AL, Fagerberg J, Lindemalm C, Osterborg A, Wersäll P (1991) Therapy of colorectal carcinoma with monoclonal antibodies (Mab17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 30: 923-931
-
(1991)
Acta Oncol
, vol.30
, pp. 923-931
-
-
Mellstedt, H.1
Frödin, J.E.2
Ragnhammar, P.3
Masucci, G.4
Ljungberg, A.5
Hjelm, A.L.6
Fagerberg, J.7
Lindemalm, C.8
Osterborg, A.9
Wersäll, P.10
-
22
-
-
1942474587
-
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
-
Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346
-
(2004)
Cancer Res
, vol.64
, pp. 2343-2346
-
-
Nahta, R.1
Hung, M.C.2
Esteva, F.J.3
-
23
-
-
3042665750
-
Phase i study of rituximab-CHOP in combination with GM-CSF in patients with follicular lymphoma
-
Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M (2004) Phase I study of rituximab-CHOP in combination with GM-CSF in patients with follicular lymphoma. Clin Cancer Res 10: 4077-4082
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4077-4082
-
-
Niitsu, N.1
Hayama, M.2
Okamoto, M.3
Khori, M.4
Higashihara, M.5
Tamaru, J.6
Hirano, M.7
-
24
-
-
22344447164
-
A new schedule of CHOP/ rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation
-
Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P (2005) A new schedule of CHOP/ rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 11: 627-636
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 627-636
-
-
Olivieri, A.1
Lucesole, M.2
Capelli, D.3
Gini, G.4
Montanari, M.5
Candela, M.6
Troiani, E.7
Scortechini, I.8
Poloni, A.9
Leoni, P.10
-
25
-
-
0033118889
-
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
-
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251
-
(1999)
Oncogene
, vol.18
, pp. 2241-2251
-
-
Pegram, M.1
Hsu, S.2
Lewis, G.3
Pietras, R.4
Beryt, M.5
Sliwkowski, M.6
Coombs, D.7
Baly, D.8
Kabbinavar, F.9
Slamon, D.10
-
26
-
-
0028997307
-
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
-
Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446
-
(1995)
Oncogene
, vol.10
, pp. 2435-2446
-
-
Pietras, R.J.1
Arboleda, J.2
Reese, D.M.3
Wongvipat, N.4
Pegram, M.D.5
Ramos, L.6
Gorman, C.M.7
Parker, M.G.8
Sliwkowski, M.X.9
Slamon, D.J.10
-
27
-
-
0027363077
-
HER-2/neu expression in node negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
-
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ (1993) HER-2/neu expression in node negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-4970
-
(1993)
Cancer Res
, vol.53
, pp. 4960-4970
-
-
Press, M.F.1
Pike, M.C.2
Chazin, V.R.3
Hung, G.4
Udove, J.A.5
Markowicz, M.6
Danyluk, J.7
Godolphin, W.8
Sliwkowski, M.9
Akita, R.10
Paterson, M.C.11
Slamon, D.J.12
-
28
-
-
0030437924
-
Anti-tumoral effect of GM-CSF with or without cyto-kines and monoclonal antibodies in solid tumors
-
Ragnhammar P (1996) Anti-tumoral effect of GM-CSF with or without cyto-kines and monoclonal antibodies in solid tumors. Med Oncol 13: 167-176
-
(1996)
Med Oncol
, vol.13
, pp. 167-176
-
-
Ragnhammar, P.1
-
29
-
-
0026664356
-
Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony stimulating factor
-
Ragnhammar P, Masucci G, Frödin JE, Hjelm AL, Mellstedt H (1992) Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony stimulating factor. Cancer Immunol Immunother 35: 158-164
-
(1992)
Cancer Immunol Immunother
, vol.35
, pp. 158-164
-
-
Ragnhammar, P.1
Masucci, G.2
Frödin, J.E.3
Hjelm, A.L.4
Mellstedt, H.5
-
30
-
-
0029039990
-
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers\-a review
-
Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers\-a review. Gene 159: 19-27
-
(1995)
Gene
, vol.159
, pp. 19-27
-
-
Ravdin, P.M.1
Chamness, G.C.2
-
31
-
-
0037479973
-
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: A pilot study
-
Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9: 2440-2446
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2440-2446
-
-
Repka, T.1
Chiorean, E.G.2
Gay, J.3
Herwig, K.E.4
Kohl, V.K.5
Yee, D.6
Miller, J.S.7
-
32
-
-
34247588567
-
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
-
Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 628-638
-
-
Scaltriti, M.1
Rojo, F.2
Ocaña, A.3
Anido, J.4
Guzman, M.5
Cortes, J.6
Di Cosimo, S.7
Matias-Guiu, X.8
Ramon Y Cajal, S.9
Arribas, J.10
Baselga, J.11
-
33
-
-
0035873815
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
-
Seidman AD, Fornier M, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595
-
(2001)
J Clin Oncol
, vol.19
, pp. 2587-2595
-
-
Seidman, A.D.1
Fornier, M.2
Esteva, F.J.3
Tan, L.4
Kaptain, S.5
Bach, A.6
Panageas, K.S.7
Arroyo, C.8
Valero, V.9
Currie, V.10
Gilewski, T.11
Theodoulou, M.12
Moynahan, M.E.13
Moasser, M.14
Sklarin, N.15
Dickler, M.16
D'Andrea, G.17
Cristofanilli, M.18
Rivera, E.19
Hortobagyi, G.N.20
Norton, L.21
Hudis, C.A.22
more..
-
34
-
-
0027517374
-
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
-
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942
-
(1993)
J Clin Oncol
, vol.11
, pp. 1936-1942
-
-
Seshadri, R.1
Firgaira, F.A.2
Horsfall, D.J.3
McCaul, K.4
Setlur, V.5
Kitchen, P.6
-
35
-
-
0344333420
-
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
-
Sjögren S, Inganäs M, Lindgren A, Homberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462-469
-
(1998)
J Clin Oncol
, vol.16
, pp. 462-469
-
-
Sjögren, S.1
Inganäs, M.2
Lindgren, A.3
Homberg, L.4
Bergh, J.5
-
36
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
37
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
38
-
-
0032851961
-
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
-
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26(4 suppl 12): 60-70
-
(1999)
Semin Oncol
, vol.26
, Issue.4 SUPPL. 12
, pp. 60-70
-
-
Sliwkowski, M.X.1
Lofgren, J.A.2
Lewis, G.D.3
Hotaling, T.E.4
Fendly, B.M.5
Fox, J.A.6
-
39
-
-
0034793479
-
Antibody-directed, effector cell-mediated tumor destruction
-
Sondel PM, Hank JA (2001) Antibody-directed, effector cell-mediated tumor destruction. Hematol Oncol Clin North Am 15: 703-721
-
(2001)
Hematol Oncol Clin North Am
, vol.15
, pp. 703-721
-
-
Sondel, P.M.1
Hank, J.A.2
-
40
-
-
0036284422
-
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo
-
Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8: 1720-1730
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1720-1730
-
-
Spiridon, C.I.1
Ghetie, M.A.2
Uhr, J.3
Marches, R.4
Li, J.L.5
Shen, G.L.6
Vitetta, E.S.7
-
41
-
-
1642339735
-
Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu
-
Stein S, DeMichele A, Domchek S, Fox K (2004) Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. Clin Breast Cancer 4(suppl 3): S117-S120
-
(2004)
Clin Breast Cancer
, vol.4
, Issue.SUPPL. 3
-
-
Stein, S.1
Demichele, A.2
Domchek, S.3
Fox, K.4
-
42
-
-
0030434818
-
Granulocyte-macrophage colony-stimulating fctor and the immune system
-
Tarr PE (1996) Granulocyte-macrophage colony-stimulating fctor and the immune system. Med Oncol 13: 133-140
-
(1996)
Med Oncol
, vol.13
, pp. 133-140
-
-
Tarr, P.E.1
-
43
-
-
0024334081
-
Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages
-
Thomassen MJ, Barna BP, Rankin D, Wiedemann HP, Ahmad M (1989) Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages. Cancer Res 49: 4086-4089
-
(1989)
Cancer Res
, vol.49
, pp. 4086-4089
-
-
Thomassen, M.J.1
Barna, B.P.2
Rankin, D.3
Wiedemann, H.P.4
Ahmad, M.5
-
44
-
-
0033159136
-
Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain
-
Tseng SH, Hsieh CL, Lin SM, Hwang LH (1999) Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. Cancer Gene Ther 6: 302-312
-
(1999)
Cancer Gene Ther
, vol.6
, pp. 302-312
-
-
Tseng, S.H.1
Hsieh, C.L.2
Lin, S.M.3
Hwang, L.H.4
-
45
-
-
0000230036
-
Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study [abstract]
-
A1846
-
Yu AL, Batova A, Alvarado C, Rao VJ, Castleberry RP (1997) Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study [abstract]. Proc Am Soc Clin Oncol 16: 513a. A1846
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Yu, A.L.1
Batova, A.2
Alvarado, C.3
Rao, V.J.4
Castleberry, R.P.5
|